福瑞達(600223.SH):未來公司將聚焦醫藥、化粧品兩大主業
格隆匯8月7日丨福瑞達(600223.SH)近期在接待機構投資者調研時表示,根據《重大資產出售協議書》的約定,公司重大資產出售事項分兩次進行交割,每次交割分兩次進行支付。截止目前,本次交易已按交易安排完成第一批次標的資產交割,第二批次標的資產將於2023年10月31日前完成交割。公司擬將收到的價款用於償還到期借款和支持醫藥健康業務發展,增強公司盈利能力和市場競爭力。
隨着上市公司地產業務的置出,公司已完成名稱變更,重新梳理髮展戰略,並於5月18日召開戰略發佈會,對外發布全新發展戰略。未來,公司將聚焦醫藥、化粧品兩大主業,做大醫藥規模、做強化粧品產業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.